Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Nealya Bell-Silva

Nurse Practitioner, Women's Health Saint Louis, MO Nurse Practitioner

NPI 1679738264 CMS profile 10750269

615 S New Ballas Rd, Saint Louis, MO 63141

Open in the dashboard

General payments

$107,264

117 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nealya Bell-Silva of Saint Louis, MO is reported in the CMS Open Payments database as having received $107,264 across 117 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Women's Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $43,306 67
2024 General $28,397 22
2023 General $32,017 22
2022 General $3,544 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nealya Bell-Silva
  • Nurse Practitioner, Women's Health median
  • Middle half of Nurse Practitioner, Women's Health
  • National median

In program year 2025, general payments to Nealya Bell-Silva were reported at $43,306. Among 3,829 Nurse Practitioner, Women's Health profiles paid that year, the median was $124 and the middle half received between $42 and $307.

Show as a table
Year Nealya Bell-Silva Nurse Practitioner, Women's Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $110 $33–$291 $132
2022 $3,544 $122 $40–$314 $149
2023 $32,017 $131 $40–$333 $160
2024 $28,397 $123 $43–$298 $164
2025 $43,306 $124 $42–$307 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Gen-Probe, Inc. $87,976 38 payments
  2. Hologic, LLC $19,098 72 payments
  3. Baxter Healthcare $84 1 payment
  4. Novo Nordisk Inc $54 3 payments
  5. Lilly USA, LLC $37 2 payments
  6. Radius Health, Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Consulting Fee $86,441 18 payments
  2. Travel and Lodging $18,351 64 payments
  3. Food and Beverage $2,387 34 payments
  4. Long term medical supply or device loan $84 1 payment
Products named General payments · program years 2022–2025
  1. Aptima $91,728 93 payments
  2. THINPREP 2000 PROCESSOR $9,886 6 payments
  3. BTX $288 2 payments
  4. Fetal Fibronectin Enzyme Immunoassay $288 2 payments
  5. Hillrom - OAE Hearing Screener $84 1 payment
  6. AFFIRM PRONE BIOPSY SYSTEM $82 1 payment
  7. Ozempic $54 3 payments
  8. RYBELSUS $54 3 payments
  9. THIRD WAVE $39 2 payments
  10. MOUNJARO $37 2 payments
  11. Other $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

117 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record